CardioExchange Archive

November 13th, 2011

TRACER: Novel Antiplatelet Vorapaxar Runs Into Trouble in ACS

Larry Husten, PHD

The novel antiplatelet vorapaxar, which blocks the thrombin receptor to inhibit platelet activation, ran into trouble in the TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) trial, which was stopped prematurely earlier this year due to safety concerns. TRACER was presented at the AHA by Ken Mahaffey and published simultaneously in the New England Journal of Medicine. […]

---

January 20th, 2011

Braunwald: Vorapaxar Problem Based on Intracranial Bleeding in Patients with History of Stroke

Larry Husten, PHD

A key detail has now emerged about the problems encountered with vorapaxar, Merck’s thrombin receptor antagonist that suffered a large setback last week. TIMI investigators in the TRA-2P TIMI 50 trial have been informed by Eugene Braunwald that the reason vorapaxar would be discontinued in patients who experienced a stroke prior to entry or during the trial […]

---

January 13th, 2011

Merck’s Thrombin Receptor Antagonist Suffers Major Setback

Larry Husten, PHD

Merck’s thrombin receptor antagonist, vorapaxar, has suffered a major setback in its clinical trial program. In one trial, TRACER, the study drug is being discontinued and the trial will be closed out. The second trial, TRA-2P TIMI 50, is being curtailed but not stopped. The actions were based on recommendations from the combined Data and […]

---